Last reviewed · How we verify
Matching Placebo for Dapagliflozin
This is a placebo control formulation with no active pharmacological mechanism.
This is a placebo control formulation with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trials of dapagliflozin.
At a glance
| Generic name | Matching Placebo for Dapagliflozin |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a matching placebo for dapagliflozin, this formulation is designed to be indistinguishable in appearance and administration from the active drug but contains no active ingredient. It is used in clinical trials to provide a control arm for comparison against the active SGLT2 inhibitor dapagliflozin.
Approved indications
- Control arm in phase 3 clinical trials of dapagliflozin
Common side effects
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (PHASE3)
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease (PHASE3)
- Dapagliflozin for Long COVID Syndrome (PHASE3)
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (PHASE3)
- Dapagliflozin in Active Lupus Nephritis (PHASE4)
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching Placebo for Dapagliflozin CI brief — competitive landscape report
- Matching Placebo for Dapagliflozin updates RSS · CI watch RSS
- AstraZeneca portfolio CI